# Reduced Intensity Haploidentical Transplant for Hematological Malignancies

> **NCT01162096** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 34 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DEVICE:** Haploidentical Allogeneic Transplantation

## Key facts

- **NCT ID:** NCT01162096
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2010-09
- **Final completion:** 2012-04
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01162096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01162096, "Reduced Intensity Haploidentical Transplant for Hematological Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01162096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*